{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:23:56Z","timestamp":1790821436927,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40618-020-01344-z","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T07:02:35Z","timestamp":1593414155000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Management and outcome of metastatic pheochromocytomas\/paragangliomas: an overview"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-5526","authenticated-orcid":false,"given":"G.","family":"De Filpo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"6","key":"1344_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine Society (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915\u20131942. https:\/\/doi.org\/10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"key":"1344_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","volume":"51","author":"AMA Berends","year":"2018","unstructured":"Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, Kerstens MN (2018) Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med 51:68\u201373. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.015","journal-title":"Eur J Intern Med"},{"issue":"19","key":"1344_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HP Neumann","year":"2002","unstructured":"Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Pe\u00e7zkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459\u20131466. https:\/\/doi.org\/10.1056\/NEJMoa020152","journal-title":"N Engl J Med"},{"issue":"5","key":"1344_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/s-0031-1301302","volume":"44","author":"AP Gimenez-Roqueplo","year":"2012","unstructured":"Gimenez-Roqueplo AP, Dahia PL, Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44(5):328\u2013333. https:\/\/doi.org\/10.1055\/s-0031-1301302","journal-title":"Horm Metab Res"},{"issue":"2","key":"1344_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","volume":"14","author":"PL Dahia","year":"2014","unstructured":"Dahia PL (2014) Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 14(2):108\u2013119. https:\/\/doi.org\/10.1038\/nrc3648","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1344_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","volume":"4","author":"I Jochmanova","year":"2018","unstructured":"Jochmanova I, Pacak K (2018) Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer 4(1):6\u20139. https:\/\/doi.org\/10.1016\/j.trecan.2017.11.001","journal-title":"Trends Cancer"},{"key":"1344_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/872713","author":"G Parenti","year":"2012","unstructured":"Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giach\u00e8 V, Mannelli M (2012) Updated and new perspectives on diagnosis, prognosis and therapy of malignant pheochromocytoma\/paraganglioma. J Oncol. https:\/\/doi.org\/10.1155\/2012\/872713","journal-title":"J Oncol"},{"issue":"3","key":"1344_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","volume":"28","author":"AK Lam","year":"2017","unstructured":"Lam AK (2017) Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 28(3):213\u2013227. https:\/\/doi.org\/10.1007\/s12022-017-9484-5","journal-title":"Endocr Pathol"},{"key":"1344_CR9","isbn-type":"print","first-page":"183","volume-title":"WHO classification of tumors of endocrine organs","author":"AS Tischler","year":"2017","unstructured":"Tischler AS, de Krijger RR (2017) Phaeochromocytoma. In: Lloyd RV, Osamura RY, Kloppel G (eds) WHO classification of tumors of endocrine organs, 4th edn. IARC Press, Lyons, pp 183\u2013189. ISBN 978-92-832-4493-6","ISBN":"https:\/\/id.crossref.org\/isbn\/9789283244936","edition":"4"},{"issue":"3","key":"1344_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00829","volume":"11","author":"SR Bornstein","year":"2004","unstructured":"Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11(3):423\u2013436. https:\/\/doi.org\/10.1677\/erc.1.00829","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1344_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96(3):717\u2013725. https:\/\/doi.org\/10.1210\/jc.2010-1946","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1344_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","volume":"15","author":"C Jimenez","year":"2013","unstructured":"Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E (2013) Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 15(4):356\u2013371. https:\/\/doi.org\/10.1007\/s11912-013-0320-x","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1344_CR13","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C (2014) Therapy of endocrine disease: treatment of\u00a0malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111\u2013R122. https:\/\/doi.org\/10.1530\/EJE-14-0113","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1344_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1210\/jc.2006-1544","volume":"92","author":"T Scholz","year":"2007","unstructured":"Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H (2007) Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92(4):1217\u20131225. https:\/\/doi.org\/10.1210\/jc.2006-1544","journal-title":"J Clin Endocrinol Metab"},{"key":"1344_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050724","author":"A Angelousi","year":"2019","unstructured":"Angelousi A, Peppa M, Chrisoulidou A, Alexandraki K, Berthon A, Faucz FR, Kassi E, Kaltsas G (2019) Malignant pheochromocytomas\/paragangliomas and ectopic hormonal secretion: a case series and review of the literature. Cancer (Basel). https:\/\/doi.org\/10.3390\/cancers11050724","journal-title":"Cancer (Basel)"},{"issue":"4","key":"1344_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1210\/er.2002-0013","volume":"24","author":"EL Bravo","year":"2003","unstructured":"Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24(4):539\u2013553. https:\/\/doi.org\/10.1210\/er.2002-0013","journal-title":"Endocr Rev"},{"issue":"5","key":"1344_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1055\/s-0031-1301339","volume":"44","author":"L Amar","year":"2012","unstructured":"Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Preibisz A, Timmers H, Plouin PF (2012) Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 44(5):385\u2013389. https:\/\/doi.org\/10.1055\/s-0031-1301339","journal-title":"Horm Metab Res"},{"issue":"4","key":"1344_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","volume":"33","author":"D Wu","year":"2009","unstructured":"Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Kriiger R, van Nederveen F, Nos\u00e9 V (2009) Observer variation in the application of the pheochromocytoma of the adrenal glande scaled score. Am J Surg Pathol 33(4):599\u2013608. https:\/\/doi.org\/10.1097\/PAS.0b013e318190d12e","journal-title":"Am J Surg Pathol"},{"key":"1344_CR19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1583::AID-CNCR28>3.0.CO;2-#","volume":"86","author":"HM Brown","year":"1999","unstructured":"Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu YR (1999) Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 86:1583\u20131589","journal-title":"Cancer"},{"issue":"2\u201303","key":"1344_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1055\/a-0715-1888","volume":"127","author":"S N\u00f6lting","year":"2019","unstructured":"N\u00f6lting S, Grossman A, Pacak K (2019) Metastatic phaeochromocytoma: spinning towards more promising treatment options. Exp Clin Endocrinol Diabetes 127(2\u201303):117\u2013128. https:\/\/doi.org\/10.1055\/a-0715-1888","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"1344_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/bf03344107","volume":"29","author":"C Fuentes","year":"2006","unstructured":"Fuentes C, Men\u00e9ndez E, Pineda J, Mart\u00ednez De Esteban JP, Anda E, Go\u00f1i MJ, Bausch B, Neumann HP (2006) The malignant potential of a succinate dehydrogenase subunit B germline mutation. J Endocrinol Invest 29(4):350\u2013352. https:\/\/doi.org\/10.1007\/bf03344107","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1344_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","volume":"19","author":"P Jimenez","year":"2017","unstructured":"Jimenez P, Tatsui C, Jessop A, Thosani S, Jimenez C (2017) Treatment for malignant pheochromocytomas and paragangliomas: 5\u00a0years of progress. Curr Oncol Rep 19(12):83. https:\/\/doi.org\/10.1007\/s11912-017-0643-0","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"1344_CR23","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K (2012) Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48(11):1739\u20131749. https:\/\/doi.org\/10.1016\/j.ejca.2011.07.016","journal-title":"Eur J Cancer"},{"issue":"9","key":"1344_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/BF03345807","volume":"15","author":"M Schlumberger","year":"1992","unstructured":"Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP, Gardet P, Parmentier C (1992) Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15(9):631\u2013642. https:\/\/doi.org\/10.1007\/BF03345807","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1344_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/MED.0000000000000476","volume":"26","author":"O Hamidi","year":"2019","unstructured":"Hamidi O (2019) Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. Curr Opin Endocrinol Diabetes Obes 26(3):146\u2013154. https:\/\/doi.org\/10.1097\/MED.0000000000000476","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"1344_CR26","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Lib\u00e9 R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E, French Group of Endocrine and Adrenal Tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks) (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98(10):4006\u20134012. https:\/\/doi.org\/10.1210\/jc.2013-1907","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1344_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1530\/EJE-15-0456","volume":"173","author":"S Thosani","year":"2015","unstructured":"Thosani S, Ayala-Ramirez M, Rom\u00e1n-Gonz\u00e1lez A, Zhou S, Thosani N, Bisanz A, Jimenez C (2015) Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. Eur J Endocrinol 173(3):377\u2013387. https:\/\/doi.org\/10.1530\/EJE-15-0456","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1344_CR28","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","volume":"24","author":"V Strajina","year":"2017","unstructured":"Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, Que FG, Nagorney DM, Young WF, Thompson GB (2017) Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series. Ann Surg Oncol 24(6):1546\u20131550. https:\/\/doi.org\/10.1245\/s10434-016-5739-5","journal-title":"Ann Surg Oncol"},{"key":"1344_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fendo.2018.00277","volume":"9","author":"C Jimenez","year":"2018","unstructured":"Jimenez C (2018) Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer. Front Endocrinol (Lausanne) 9:277. https:\/\/doi.org\/10.3389\/fendo.2018.00277","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1344_CR30","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF Jr, I\u00f1iguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S, Bancos I (2017) Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 102(9):3296\u20133305. https:\/\/doi.org\/10.1210\/jc.2017-00992","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1344_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2018","unstructured":"Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C (2018) Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg 268(1):172\u2013178. https:\/\/doi.org\/10.1097\/SLA.0000000000002195","journal-title":"Ann Surg"},{"issue":"4","key":"1344_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","volume":"109","author":"SD Averbuch","year":"1988","unstructured":"Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109(4):267\u2013273. https:\/\/doi.org\/10.7326\/0003-4819-109-4-267","journal-title":"Ann Intern Med"},{"issue":"5","key":"1344_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP (2014) Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 81(5):642\u2013651. https:\/\/doi.org\/10.1111\/cen.12542","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1344_CR34","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1210\/jc.2008-2697","volume":"94","author":"K Nomura","year":"2009","unstructured":"Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, Takano K (2009) Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 94(8):2850\u20132856. https:\/\/doi.org\/10.1210\/jc.2008-2697","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1344_CR35","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C (2012) Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118(11):2804\u20132812. https:\/\/doi.org\/10.1002\/cncr.26577","journal-title":"Cancer"},{"issue":"2","key":"1344_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","volume":"8","author":"S Asai","year":"2017","unstructured":"Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M (2017) Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas. Horm Cancer 8(2):108\u2013118. https:\/\/doi.org\/10.1007\/s12672-017-0284-7","journal-title":"Horm Cancer"},{"issue":"8","key":"1344_CR37","doi-asserted-by":"publisher","first-page":"L51","DOI":"10.1530\/ERC-17-0086","volume":"24","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma DA, Loaiza-Bonilla A, Fraker DL, Nathanson KL, Cohen DL (2017) SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer 24(8):L51\u2013L55. https:\/\/doi.org\/10.1530\/ERC-17-0086","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"1344_CR38","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10571-018-0579-4","volume":"38","author":"I Jawed","year":"2018","unstructured":"Jawed I, Velarde M, D\u00e4rr R, Wolf KI, Adams K, Venkatesan AM, Balasubramaniam S, Poruchynsky MS, Reynolds JC, Pacak K, Fojo T (2018) Continued tumor reduction of metastatic pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy. Cell Mol Neurobiol 38(5):1099\u20131106. https:\/\/doi.org\/10.1007\/s10571-018-0579-4","journal-title":"Cell Mol Neurobiol"},{"issue":"11","key":"1344_CR39","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, D\u00e9andreis D, Borget I, Loriot C, Chougnet C, Letouz\u00e9 E, Young J, Amar L, Bertherat J, Lib\u00e9 R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135(11):2711\u20132720. https:\/\/doi.org\/10.1002\/ijc.28913","journal-title":"Int J Cancer"},{"key":"1344_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12688\/f1000research.13995.1","volume":"30","author":"R Toledo","year":"2018","unstructured":"Toledo R, Jimenez C (2018) Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factors inhibitors. F1000Research 30:7. https:\/\/doi.org\/10.12688\/f1000research.13995.1","journal-title":"F1000Research"},{"issue":"12","key":"1344_CR41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"O\u2019Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Onley HJ, Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ (2019) A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 120(12):1113\u20131119. https:\/\/doi.org\/10.1038\/s41416-019-0474-x","journal-title":"Br J Cancer"},{"issue":"2","key":"1344_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","volume":"57","author":"S Jasim","year":"2017","unstructured":"Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC (2017) Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma. Endocrine 57(2):220\u2013225. https:\/\/doi.org\/10.1007\/s12020-017-1359-5","journal-title":"Endocrine"},{"key":"1344_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/jco.2015.337_suppl.457","volume":"33","author":"M Emmanuel","year":"2015","unstructured":"Emmanuel M, Pichun B, Edgerly M, Velarde M, Bates SE, Daerr R, Adams K, Pacak K, Fojo T (2015) Phase II clinical trial of axitinib in metastatic pheochromocytomas and paragangliomas (P\/PG): preliminary results. J Clin Oncol 33:457. https:\/\/doi.org\/10.1200\/jco.2015.337_suppl.457","journal-title":"J Clin Oncol"},{"key":"1344_CR44","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0043","author":"C Jimenez","year":"2020","unstructured":"Jimenez C, Fazeli S, Roman-Gonzalez A (2020) Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/ERC-20-0043","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1344_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","volume":"59","author":"G Gravel","year":"2018","unstructured":"Gravel G, Leboulleux S, Tselikas L, Fassio F, Berraf M, Berdelou A, Ba B, Hescot S, Hadoux J, Schlumberger M, Al Ghuzlan A, Nguyen F, Faron M, de Baere T, Baudin E, Deschamps F (2018) Prevention of serious skeletal-related events by interventional techniques in patients with malignant paraganglioma and pheochromocytoma. Endocrine 59(3):547\u2013554. https:\/\/doi.org\/10.1007\/s12020-017-1515-y","journal-title":"Endocrine"},{"issue":"4","key":"1344_CR46","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C (2013) Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98(4):1492\u20131497. https:\/\/doi.org\/10.1210\/jc.2012-4231","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1344_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2017","unstructured":"Breen W, Bancos I, Young WF Jr, Bible KC, Laack NN, Foote RL, Hallemeier CL (2017) External beam radiation therapy for advanced\/unresectable\u00a0malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol 3(1):25\u201329. https:\/\/doi.org\/10.1016\/j.adro.2017.11.002","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"1344_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/cancers11020195","volume":"11","author":"J Kohlenberg","year":"2019","unstructured":"Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, Bancos I, Young W Jr (2019) Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers (Basal) 11(2):195. https:\/\/doi.org\/10.3390\/cancers11020195","journal-title":"Cancers (Basal)"},{"issue":"7","key":"1344_CR49","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/cancers11071018","volume":"11","author":"C Jimenez","year":"2019","unstructured":"Jimenez C, Erwin W, Chasen B (2019) Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine. Cancers (Basal) 11(7):1018. https:\/\/doi.org\/10.3390\/cancers11071018","journal-title":"Cancers (Basal)"},{"issue":"4","key":"1344_CR50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP (2014) (131)I-MIBG\u00a0therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 80(4):487\u2013501. https:\/\/doi.org\/10.1111\/cen.12341","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1344_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/bjc.2013.365","volume":"109","author":"WC Sze","year":"2013","unstructured":"Sze WC, Grossman AB, Goddard I, Amendra D, Shieh SC, Plowman PN, Drake WM, Akker SA, Druce MR (2013) Sequelae and survivorship in patients treated with (131)I-MIBG\u00a0therapy. Br J Cancer 109(3):565\u2013572. https:\/\/doi.org\/10.1038\/bjc.2013.365","journal-title":"Br J Cancer"},{"issue":"4","key":"1344_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000499497","volume":"109","author":"IYF Mak","year":"2019","unstructured":"Mak IYF, Hayes AR, Khoo B, Grossman A (2019) Peptide receptor radionuclide therapy as a novel treatment for metastatic and invasive phaeochromocytoma and paraganglioma. Neuroendocrinology 109(4):287\u2013298. https:\/\/doi.org\/10.1159\/000499497","journal-title":"Neuroendocrinology"},{"issue":"5","key":"1344_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo VA, Mahmood S, Wong V, Jimenez C (2019) Efficacy and safety of high-specific-activity\u00a0131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med 60(5):623\u2013630. https:\/\/doi.org\/10.2967\/jnumed.118.217463","journal-title":"J Nucl Med"},{"issue":"25","key":"1344_CR54","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27(25):4162\u20134168. https:\/\/doi.org\/10.1200\/JCO.2008.21.3496","journal-title":"J Clin Oncol"},{"issue":"4","key":"1344_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","volume":"115","author":"K Nastos","year":"2017","unstructured":"Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, Caplin M, Khoo B (2017) Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas. J Surg Oncol 115(4):425\u2013434. https:\/\/doi.org\/10.1002\/jso.24553","journal-title":"J Surg Oncol"},{"issue":"1","key":"1344_CR56","doi-asserted-by":"publisher","first-page":"e000530","DOI":"10.1136\/jitc-2020-000530","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin CC, Sharma S, Ochoa de Olza M, Varga A, Taylor M, Schellens JHM, Wu H, Sun H, Silva AP, Faris J, Mataraza J, Cameron S, Bauer TM (2020) A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 8(1):e000530. https:\/\/doi.org\/10.1136\/jitc-2020-000530","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1344_CR57","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1055\/s-0029-1220687","volume":"41","author":"MR Druce","year":"2009","unstructured":"Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB (2009) Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41(9):697\u2013702. https:\/\/doi.org\/10.1055\/s-0029-1220687","journal-title":"Horm Metab Res"},{"issue":"24","key":"1344_CR58","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1002\/cncr.27675","volume":"118","author":"DY Oh","year":"2012","unstructured":"Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ (2012) Phase 2 study of\u00a0everolimus\u00a0monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas. Cancer 118(24):6162\u20136170. https:\/\/doi.org\/10.1002\/cncr.27675","journal-title":"Cancer"},{"issue":"2","key":"1344_CR59","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1210\/en.2012-1854","volume":"154","author":"A Giubellino","year":"2013","unstructured":"Giubellino A, Bullova P, N\u00f6lting S, Turkova H, Powers JF, Liu Q, Guichard S, Tischler AS, Grossman AB, Pacak K (2013) Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 154(2):646\u2013655. https:\/\/doi.org\/10.1210\/en.2012-1854","journal-title":"Endocrinology"},{"issue":"2","key":"1344_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0032-1331211","volume":"45","author":"J Matro","year":"2013","unstructured":"Matro J, Giubellino A, Pacak K (2013) Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Horm Metab Res 45(2):147\u2013153. https:\/\/doi.org\/10.1055\/s-0032-1331211","journal-title":"Horm Metab Res"},{"issue":"3","key":"1344_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401\u2013406. https:\/\/doi.org\/10.1200\/JCO.2005.03.6046","journal-title":"J Clin Oncol"},{"key":"1344_CR62","doi-asserted-by":"publisher","first-page":"7185973","DOI":"10.1155\/2019\/7185973","volume":"2019","author":"ML Shindorf","year":"2019","unstructured":"Shindorf ML, Chaudhuri PK (2019) Single-agent thalidomide for treatment of malignant paraganglioma of the organ of zuckerkandl. Case Rep Med 2019:7185973. https:\/\/doi.org\/10.1155\/2019\/7185973","journal-title":"Case Rep Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-020-01344-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T23:17:37Z","timestamp":1624922257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-020-01344-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01344-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"For this type of study, informed consent is not\nrequired.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}